MTOR and cytomegalovirus infection: Current clinical treatment for CAV is primarily focused on preventative strategies, including CMV infection prevention, rejection avoidance, vascular risk factor management, and specific pharmacotherapies, such as statins and mammalian target of rapamycin (mTOR) inhibitors that reduce the development of disease.